Halozyme Therapeutics, Inc. reported significant financial growth in its latest quarterly results, with total revenues reaching $376.7 million for the three months ended March 31, 2026, compared to $264.9 million in the same period last year, marking a 42.2% increase. The company's net income also rose to $150.0 million, or $1.27 per share, up from $118.1 million, or $0.96 per share, in the prior year. This growth was primarily driven by a substantial increase in royalties, which surged by 43% to $240.7 million, largely due to strong sales of partner products utilizing Halozyme's ENHANZE technology.
In terms of operational changes, Halozyme's acquisition of Elektrofi, completed in November 2025, has begun to show positive impacts on its financials. The acquisition, valued at approximately $810.4 million, is expected to enhance Halozyme's drug delivery technology offerings. Additionally, the company has expanded its collaborations, including a new agreement with GSK for multiple oncology targets and a partnership with Oruka for the Hypercon technology, which is designed to improve drug delivery methods.
The company also reported a notable increase in product sales, which rose 67% to $130.4 million, driven by a 172% increase in bulk rHuPH20 sales. This growth reflects heightened demand from partners, as well as contributions from proprietary products like XYOSTED. However, revenues from collaborative agreements decreased by 70% to $5.6 million, primarily due to the timing of milestone achievements, which can fluctuate significantly from quarter to quarter.
Halozyme's balance sheet showed a strong position with total assets of $2.67 billion as of March 31, 2026, up from $2.53 billion at the end of 2025. The company reported cash and cash equivalents of $309.7 million, a significant increase from $133.8 million at the end of the previous year. This liquidity, combined with anticipated revenue growth, positions Halozyme well for future investments and operational needs.
Looking ahead, Halozyme expects continued growth in royalty revenues driven by increasing sales of ENHANZE partner products, particularly DARZALEX SC, Phesgo, and VYVGART Hytrulo. The company remains optimistic about its strategic partnerships and product pipeline, which are anticipated to contribute positively to its financial performance in the coming quarters.
About HALOZYME THERAPEUTICS, INC.
Halozyme Therapeutics, Inc. develops innovative drug delivery and auto-injector technologies, primarily utilizing its ENHANZE platform with proprietary enzyme rHuPH20. It licenses its technology to biopharmaceutical partners for subcutaneous formulations, enhancing drug absorption and patient convenience. The company also markets proprietary products like Hylenex and XYOSTED, supporting collaborations with major pharma firms to improve injectable therapies and expand treatment options globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.